Navigation Links
Scripps Research discoveries lead to newly approved drug for infant respiratory distress syndrome
Date:3/7/2012

LA JOLLA, CA - Scientific advances at The Scripps Research Institute have led to a new drug Surfaxin (lucinactant), approved today by the U.S. Food and Drug Administration (FDA) to treat infant respiratory distress syndrome.

"I am excited that our scientific findings will help save lives," said Charles Cochrane, MD, professor emeritus at Scripps Research. "Many years of work in our basic research laboratory at The Scripps Research Institute made this landmark development possible."

Respiratory distress syndrome (also known as neonatal respiratory distress syndrome) is a life-threatening condition affecting pre-term infants. The more premature an infant is, the more likely he or she is to suffer from it and die.

The condition occurs when infants are born prior to the time when natural surfactant is made in their lungs. Surfactant is a liquid that coats the inside of the lungs, helping to keep the air sacs open and making normal breathing possible. Without enough surfactant, the lungs collapse and the body can be starved of oxygen.

In addition to mechanical ventilation, current treatments for pre-term infants involve using surfactants derived from chopped cow or pig lungs. However, animal-derived surfactants are expensive, contain material that can be injurious to the lungs, and cannot be produced in quantities sufficient to treat pre-term infants worldwide. In addition, animal-derived surfactants can only be used once since they cause an immune reaction; in contrast, the new synthetic surfactant is not immunogenic.

The Cochrane lab first created a synthetic version of surfactant in the 1990s, mimicking a natural peptide known as Surfactant Protein B; the inventors of the technology are Cochrane and Susan Revak. After this formative work at Scripps Research, the therapy was developed by Discovery Labs of Warrington, PA, which oversaw the three phases of clinical trials required by the FDA. These clinic trials provided data on the drug's success.


'/>"/>

Contact: Mika Ono
mikaono@scripps.edu
Scripps Research Institute
Source:Eurekalert  

Related biology news :

1. Scripps research team solves structure of beneficial virus
2. Scripps research team sheds light on immune system suppression
3. Scripps Florida scientists awarded $1.5M to fight major water and food parasites
4. Scripps research scientists identify compounds for stem-cell production from adult cells
5. Scripps research scientists identify blood component that turns bacteria virulent
6. Scripps research team defines new painkilling chemical pathway
7. Dolphin population stunted by fishing activities, Scripps/NOAA study finds
8. Scripps Research scientists shed light on how DNA is unwound so that its code can be read
9. Scripps scientists develop first examples of RNA that replicates itself indefinitely
10. Scripps scientists create first crystal structure of an intermediate particle in virus assembly
11. Historical photographs expose decline in Floridas reef fish, new Scripps study finds
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Scripps Research discoveries lead to newly approved drug for infant respiratory distress syndrome
(Date:5/11/2020)... HOUSTON (PRWEB) , ... May 11, 2020 , ... ... generation remote monitoring software platform for patients with implanted cardiac devices. The Octagos ... data using one portal. The software greatly simplifies the management of remote transmissions ...
(Date:5/1/2020)... ... April 30, 2020 , ... Flagship ... Corritori Consulting Inc., a biopharmaceutical and regulatory services advisor. The companies now deliver ... Flagship and Corritori are taking a collaborative approach to empower more confident and ...
(Date:4/30/2020)... ... April 28, 2020 , ... ... Lachman Consultants latest effort in providing timely and critical information to life science ... social distancing and health safety concerns. , “Providing the most up-to-date actionable guidance ...
Breaking Biology News(10 mins):
(Date:5/30/2020)... ... May 29, 2020 , ... Medrio, Inc., the leading ... markets, has enabled Cytovale, Inc., a medical technology company dedicated to revolutionizing diagnostics ... their first patient in (FPI) in just seven days. The Cytovale technology will ...
(Date:5/21/2020)... ... May 21, 2020 , ... ... trials will cause long-term harm , Contrary to conventional wisdom that says the ... finds many companies will emerge from the pandemic commercially weaker, dealing with ...
(Date:5/15/2020)... ... May 14, 2020 , ... ... open heart surgeries before becoming adults. The reason: there are no ... this critical unmet need, the Department of Defense has awarded Draper, Boston Children’s ...
(Date:5/14/2020)... ... May 13, 2020 , ... ... Future Lab: Optimizing Workflows in the Life Science Lab . The comprehensive information ... lab, from water purification and liquid handling to contamination control. , The content ...
Breaking Biology Technology: